Domagrozumab, a novel antibody, is currently subjected to extensive scientific exploration focused on its potential in cancer therapy. Initial preclinical evidence indicate that this experimental agent selectively targets a specific marker expressed on tumor cells, causing tissue apoptosis and inhibition of cancerous development. Current trials are